Actelion, the Swiss biotechnology firm, is to list on the SWS Swiss Exchange's main market segment, following the near collapse last month of the SWX New Market, where it is currently listed.
The company's shares will be switched from the failed growth market to the main market on September 9 2002, where they will trade under its existing trading symbol.